Highlights and Quick Summary
- Ending Cash for the quarter ending September 30, 2023 was $8.85 Million (a -82.19% decrease compared to previous quarter)
- Year-over-year quarterly Ending Cash decreased by -118.69%
- Annual Ending Cash for 2022 was $76.8 Million (a -72.55% decrease from previous year)
- Annual Ending Cash for 2021 was $280 Million (a 290.37% increase from previous year)
- Annual Ending Cash for 2020 was $71.7 Million (a 416.78% increase from previous year)
- Twelve month Ending Cash ending September 30, 2023 was $39.5 Million (a -158.08% decrease compared to previous quarter)
- Twelve month trailing Ending Cash decreased by -48.58% year-over-year
Trailing Ending Cash for the last four month:
| 30 Sep '23 | 30 Jun '23 | 31 Mar '23 | 31 Dec '22 |
|---|---|---|---|
| $39.5 Million | $-68 Million | $-146 Million | $76.8 Million |
Visit stockrow.com/ABSI
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Ending Cash of Absci Corporation
Most recent Ending Cashof ABSI including historical data for past 10 years.Interactive Chart of Ending Cash of Absci Corporation
Absci Corporation Ending Cash for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2023 | $8.85 | $49.7 | $28.32 | – | – |
| 2022 | $-47.35 | $-98.69 | $-27.98 | $250.86 | $76.84 |
| 2021 | $-26.69 | $179.82 | $-58.33 | $185.12 | $279.93 |
| 2020 | $60.96 | $-3.75 | $2.68 | $11.82 | $71.71 |
| 2019 | $13.88 | – | – | – | $13.88 |
Business Profile of Absci Corporation
Sector: Healthcare
Industry: Biotechnology